Vector Oncology chosen as Actinium’s CRO partner in PhII cancer trial

Actinium Pharmaceuticals ($ATNM) has partnered up with Memphis, TN-based CRO Vector Oncology to help it with a midstage study of its experimental blood cancer med Actimab-A.

The second phase of testing comes after the biotech recently finishes off its small Phase I in 18 older patients with newly diagnosed acute myeloid leukemia (AML).

Phase II will focus on the highest doses used in its first studies along with more patients, 53 in total, in an open-label test. The trial is slated to start later this year, with interim data to be posted halfway through 2017, according to a statement from both companies.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

 “We are delighted to be working with Vector Oncology for our upcoming Phase II clinical trial,” stated Dragan Cicic, Actinium’s CMO.

“Vector Oncology displayed an expertise in hematology clinical trials with an emphasis on Phase II studies, which gives us great confidence in our selection. We look forward to working with Vector Oncology and to benefiting from their robust clinical capabilities.”

Sean Hart, EVP and MD at Vector Oncology, said: “Vector Oncology is excited to be working with Actinium as a member of this important team. Since our first interaction with Actinium, all team members involved have committed to getting this important product in the hands of oncology professionals as soon as possible to advance the research efforts. We very much look forward to an exciting future together.” 

Suggested Articles

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.